Yasumichi Kuwahara

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 12

Top Topics

Combination Therapy

Dna Methylation

Top Venues

Cancer discovery

Molecules and cells

This page only lists publications with an associated author ORCID identifier.

Publications

Yaniv Kazansky, Daniel Cameron, Helen S Mueller, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Yasumichi Kuwahara, Romel Somwar, Marc Ladanyi, Rui Qu, Elisa De Stanchina, Filemon Dela Cruz, Andrew L Kung, Mrinal M Gounder, Alex Kentsis
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy. Cancer discovery 14 (6) (2024)
Yaniv Kazansky, Daniel Cameron, Helen S Mueller, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Yasumichi Kuwahara, Romel Somwar, Marc Ladanyi, Rui Qu, Elisa De Stanchina, Filemon Dela Cruz, Andrew L Kung, Mrinal M Gounder, Alex Kentsis
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy. Cancer discovery 14 (6) (2024)
Yaniv Kazansky, Daniel Cameron, Helen S Mueller, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Yasumichi Kuwahara, Romel Somwar, Marc Ladanyi, Rui Qu, Elisa De Stanchina, Filemon Dela Cruz, Andrew L Kung, Mrinal M Gounder, Alex Kentsis
Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. Cancer discovery (2024)
Yaniv Kazansky, Daniel Cameron, Helen S Mueller, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Yasumichi Kuwahara, Romel Somwar, Marc Ladanyi, Rui Qu, Elisa De Stanchina, Filemon Dela Cruz, Andrew L Kung, Mrinal M Gounder, Alex Kentsis
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy. Cancer discovery 14 (6) (2024)
Yaniv Kazansky, Daniel Cameron, Helen S Mueller, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Yasumichi Kuwahara, Romel Somwar, Marc Ladanyi, Rui Qu, Elisa De Stanchina, Filemon Dela Cruz, Andrew L Kung, Mrinal M Gounder, Alex Kentsis
Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. Cancer discovery (2024)
Yaniv Kazansky, Daniel Cameron, Helen S Mueller, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Yasumichi Kuwahara, Romel Somwar, Marc Ladanyi, Rui Qu, Elisa De Stanchina, Filemon Dela Cruz, Andrew L Kung, Mrinal M Gounder, Alex Kentsis
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy. Cancer discovery 14 (6) (2024)
Yaniv Kazansky, Daniel Cameron, Helen S Mueller, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Yasumichi Kuwahara, Romel Somwar, Marc Ladanyi, Rui Qu, Elisa De Stanchina, Filemon Dela Cruz, Andrew L Kung, Mrinal M Gounder, Alex Kentsis
Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. Cancer discovery (2024)
Yaniv Kazansky, Daniel Cameron, Helen S Mueller, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Yasumichi Kuwahara, Romel Somwar, Marc Ladanyi, Rui Qu, Elisa De Stanchina, Filemon Dela Cruz, Andrew L Kung, Mrinal M Gounder, Alex Kentsis
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy. Cancer discovery 14 (6) (2024)
Masamitsu Mikami, Tatsuya Masuda, Takuya Kanatani, Mina Noura, Katsutsugu Umeda, Hidefumi Hiramatsu, Hirohito Kubota, Tomoo Daifu, Atsushi Iwai, Etsuko Yamamoto Hattori, Kana Furuichi, Saho Takasaki, Sunao Tanaka, Yasuzumi Matsui, Hidemasa Matsuo, Masahiro Hirata, Tatsuki R Kataoka, Tatsutoshi Nakahata, Yasumichi Kuwahara, Tomoko Iehara, Hajime Hosoi, Yoichi Imai, Junko Takita, Hiroshi Sugiyama, Souichi Adachi, Yasuhiko Kamikubo
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors. Molecules and cells 45 (12) (2022)
Masamitsu Mikami, Tatsuya Masuda, Takuya Kanatani, Mina Noura, Katsutsugu Umeda, Hidefumi Hiramatsu, Hirohito Kubota, Tomoo Daifu, Atsushi Iwai, Etsuko Yamamoto Hattori, Kana Furuichi, Saho Takasaki, Sunao Tanaka, Yasuzumi Matsui, Hidemasa Matsuo, Masahiro Hirata, Tatsuki R Kataoka, Tatsutoshi Nakahata, Yasumichi Kuwahara, Tomoko Iehara, Hajime Hosoi, Yoichi Imai, Junko Takita, Hiroshi Sugiyama, Souichi Adachi, Yasuhiko Kamikubo
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors. Molecules and cells 45 (12) (2022)
Masamitsu Mikami, Tatsuya Masuda, Takuya Kanatani, Mina Noura, Katsutsugu Umeda, Hidefumi Hiramatsu, Hirohito Kubota, Tomoo Daifu, Atsushi Iwai, Etsuko Yamamoto Hattori, Kana Furuichi, Saho Takasaki, Sunao Tanaka, Yasuzumi Matsui, Hidemasa Matsuo, Masahiro Hirata, Tatsuki R Kataoka, Tatsutoshi Nakahata, Yasumichi Kuwahara, Tomoko Iehara, Hajime Hosoi, Yoichi Imai, Junko Takita, Hiroshi Sugiyama, Souichi Adachi, Yasuhiko Kamikubo
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors. Molecules and cells 45 (12) (2022)
Masamitsu Mikami, Tatsuya Masuda, Takuya Kanatani, Mina Noura, Katsutsugu Umeda, Hidefumi Hiramatsu, Hirohito Kubota, Tomoo Daifu, Atsushi Iwai, Etsuko Yamamoto Hattori, Kana Furuichi, Saho Takasaki, Sunao Tanaka, Yasuzumi Matsui, Hidemasa Matsuo, Masahiro Hirata, Tatsuki R Kataoka, Tatsutoshi Nakahata, Yasumichi Kuwahara, Tomoko Iehara, Hajime Hosoi, Yoichi Imai, Junko Takita, Hiroshi Sugiyama, Souichi Adachi, Yasuhiko Kamikubo
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors. Molecules and cells 45 (12) (2022)